You are here

Vascular & Endovascular


After 30 days of follow-up, 92.7 percent of patients with atrial fibrillation at high-risk for stroke who were implanted with the Watchman device did not have any serious adverse events, according to an analysis of an international registry. In addition, 98.5 percent of patients had a successful implantation, which was defined as deployment and release of the device into the left atrial appendage.


Recent Headlines

Researchers identify molecule that may help patients recover after strokes

Researchers discovered a molecule that may be a potential therapy for patients recovering from a stroke. The molecule, known as growth and differentiation factor 10 (GDF10), is activated early after stroke, according to researchers from the department of neurology at the University of California, Los Angeles.

Stent retrievers make Cleveland Clinic’s top 10 medical innovations for 2016

As part of its annual Medical Innovation Summit, the Cleveland Clinic released its top 10 medical innovations for 2016. The list of the technologies that will have the biggest impact in healthcare included neurovascular stent retrievers, which are used after patients suffer an ischemic stroke.

Cook Medical expands voluntary recall of angiographic catheters

Cook Medical announced that it has expanded its voluntary recall of angiographic catheters to include all lots of specific sizes. 

TCT.15: Drug-coated balloon is superior to PTA in patients with peripheral artery disease

After two years of follow up, patients with peripheral artery disease who received a drug-coated balloon had significantly higher primary patency and a significantly lower rate of clinically driven target lesion revascularization compared with patients who received conventional percutaneous transluminal angioplasty (PTA).

TCT.15: Stent retriever endovascular therapy improves clinical outcomes versus standard stroke therapy

A meta-analysis of five randomized controlled trials found that performing endovascular therapy with stent retrievers was safe and effective in managing acute ischemic stroke and led to a significant improvement in functional clinical outcomes compared with standard therapy.

FDA approves combination drug to treat pulmonary arterial hypertension

The FDA approved the combination of ambrisentan and tadalafil to reduce the risks of disease progression and hospitalization for worsening pulmonary arterial hypertension (PAH) and improve exercise ability.

Medtronic agrees to acquire Lazarus Effect to expand its neurovascular business

Medtronic agreed to acquire Lazarus Effect, a medical device company with an acute ischemic stroke product that is approved in Europe but not in the U.S. The deal, which is subject to customary closing conditions, is an all-cash transaction valued at $100 million.

Medtronic acquires Medina Medical to strengthen its neurovascular division

Medtronic acquired Medina Medical, a medical device company developing a device to treat cerebral aneurysms. Medtronic had previously invested and held an ownership stake in Medina Medical, which is based in Menlo Park, Calif.

Cardiologists begin implanting patients with the Watchman device

Hospitals across the U.S. are beginning to implant patients with the Watchman left atrial appendage closure device, which the FDA approved in March.

Working long hours is associated with increased risk of stroke

Employees who work 55 or more hours per week had a higher risk of stroke compared with those who work standard hours, according to a cumulative random-effects meta-analysis of published and unpublished data.